Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 40HER2 Positive Metastatic Breast Cancer 4Breast Diseases 4Brain Neoplasms 4Carcinoma, Non-Small-Cell Lung 3Stomach Neoplasms 2HER2-positive Breast Cancer 2Colorectal Neoplasms 2Advanced Breast Cancer 2Triple Negative Breast Neoplasms 1Solid Tumor 1Salivary Gland Neoplasms 1Pathologic Complete Response 1Neoplasm Metastasis 1Neoadjuvant Treatment for HER2-positive, ER-positive Breast Cancer 1HER2-positive Metastatic Breast Cancer 1HER2+ Early or Locally Advanced Breast Cancer 1HER2+ Breast Cancer 1HER2 Positive Gastric Cancer 1HER2 Positive Breast Cancer 1HER-2 Positive Colorectal Cancer 1Estrogen Receptor-positive Breast Cancer 1Digestive System Neoplasms 1Carcinoma, Transitional Cell 1

Interventions

Folfox protocol 3Drug Therapy 3Cisplatin 3apatinib 2anlotinib 2Paclitaxel 2Oxaliplatin 2Fluorouracil 2Capecitabine 2sintilimab 1pyrotinib 1pemigatinib 1huachansu 1donafenib 1Trastuzumab 1Sorafenib 1Radiotherapy 1Physical Conditioning, Human 1Microspheres 1Leucovorin 1Immune Checkpoint Inhibitors 1Docetaxel 1Chemoradiotherapy 1Bevacizumab 1Aspirin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Digestive System Neoplasms × pyrotinib × Clear all
NCT04960943 2021-07-14

Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors

Fudan University

Phase 2 Unknown
60 enrolled
Gastrointestinal

Digestive System Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡